Alexa B Schrock1, Garrett M Frampton1, James Suh1, Zachary R Chalmers1, Mark Rosenzweig1, Rachel L Erlich1, Balazs Halmos2, Jonathan Goldman3, Patrick Forde4, Kurt Leuenberger5, Nir Peled6, Gregory P Kalemkerian7, Jeffrey S Ross8, Philip J Stephens1, Vincent A Miller1, Siraj M Ali1, Sai-Hong Ignatius Ou9. 1. Foundation Medicine, Inc., Cambridge, Massachusetts. 2. Montefiore Medical Center, Bronx, New York. 3. Hematology and Oncology, University of California Los Angeles Medical Center, Santa Monica, California. 4. Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland. 5. Oncology Hematology Care, Inc., Cincinnati, Ohio. 6. Thoracic Cancer Unit, Davidoff Cancer Center, Rabin Medical Center, Petach Tiqwa, Israel. 7. University of Michigan Cancer Center, Ann Arbor, Michigan. 8. Foundation Medicine, Inc., Cambridge, Massachusetts; Department of Pathology, Albany Medical College, Albany, New York. 9. Chao Family Comprehensive Cancer Center, University of California Irvine School of Medicine, Orange, California. Electronic address: Ignatius.ou@uci.edu.
Abstract
BACKGROUND: The hepatocyte growth factor receptor gene (MET) exon 14 skipping (METex14) has recently been described a potential driver alteration in lung cancer targetable by mesenchymal-to-epithelial transition factor (MET) tyrosine kinase inhibitors (TKIs). METHODS: Well-validated hybrid capture-based comprehensive genomic profiling was performed at the request of individual treating physicians. RESULTS: Of 11,205 lung cancers profiled by comprehensive genomic profiling, 298 (2.7%) carcinomas harbored alterations predicted to cause METex14, including adenosquamous (8.2%), sarcomatoid (7.7%), histologic subtype not otherwise specified (3.0%), adenocarcinoma (2.9%), squamous cell (2.1%), large cell (0.8%), and SCLC (0.2%). Acinar features were present in 24% of the METex14 samples. Six cases (2%) harbored MET Y1003X mutations affecting binding of the MET-negative regulator, E3 ubiquitin protein ligase. The median age of all patients with METex14 was 73 years (range 43-95) and 60% were female. Concurrent, murine double minute gene (MDM2) amplification, cyclin-dependent kinase 4 gene (CDK4) amplification, and EGFR amplification were observed in 35%, 21%, and 6.4% of patients with METex14, respectively. KRAS mutation was observed in 3% of cases. Concurrent MET amplification (METamp) (median copy number 10) was identified in 15% of METex14 samples. Significant differences in tumor mutational burden and type of the METex14 alterations were observed between the METamp and non-METamp samples. Response to MET TKI was observed in both in patients with METamp and in patients without METamp METex14. CONCLUSION: Diverse targetable METex14 alterations were identified in patients with NSCLC across age groups, including elderly patients, and in all major NSCLC histologic subtypes with an overall frequency of 2.7%. These findings support the use of hybrid capture-based molecular profiling across NSCLC subtypes to identify patients who will potentially benefit from MET TKIs.
BACKGROUND: The hepatocyte growth factor receptor gene (MET) exon 14 skipping (METex14) has recently been described a potential driver alteration in lung cancer targetable by mesenchymal-to-epithelial transition factor (MET) tyrosine kinase inhibitors (TKIs). METHODS: Well-validated hybrid capture-based comprehensive genomic profiling was performed at the request of individual treating physicians. RESULTS: Of 11,205 lung cancers profiled by comprehensive genomic profiling, 298 (2.7%) carcinomas harbored alterations predicted to cause METex14, including adenosquamous (8.2%), sarcomatoid (7.7%), histologic subtype not otherwise specified (3.0%), adenocarcinoma (2.9%), squamous cell (2.1%), large cell (0.8%), and SCLC (0.2%). Acinar features were present in 24% of the METex14 samples. Six cases (2%) harbored MET Y1003X mutations affecting binding of the MET-negative regulator, E3 ubiquitin protein ligase. The median age of all patients with METex14 was 73 years (range 43-95) and 60% were female. Concurrent, murine double minute gene (MDM2) amplification, cyclin-dependent kinase 4 gene (CDK4) amplification, and EGFR amplification were observed in 35%, 21%, and 6.4% of patients with METex14, respectively. KRAS mutation was observed in 3% of cases. Concurrent MET amplification (METamp) (median copy number 10) was identified in 15% of METex14 samples. Significant differences in tumor mutational burden and type of the METex14 alterations were observed between the METamp and non-METamp samples. Response to MET TKI was observed in both in patients with METamp and in patients without METamp METex14. CONCLUSION: Diverse targetable METex14 alterations were identified in patients with NSCLC across age groups, including elderly patients, and in all major NSCLC histologic subtypes with an overall frequency of 2.7%. These findings support the use of hybrid capture-based molecular profiling across NSCLC subtypes to identify patients who will potentially benefit from MET TKIs.
Authors: Cristina Aguado; Ana Giménez-Capitán; Niki Karachaliou; Ana Pérez-Rosado; Santiago Viteri; Daniela Morales-Espinosa; Rafael Rosell Journal: Transl Lung Cancer Res Date: 2016-10
Authors: Mark M Awad; Giulia C Leonardi; Sasha Kravets; Suzanne E Dahlberg; Alexander Drilon; Sinead A Noonan; D Ross Camidge; Sai-Hong I Ou; Daniel B Costa; Shirish M Gadgeel; Conor E Steuer; Patrick M Forde; Viola W Zhu; Yoko Fukuda; Jeffrey W Clark; Pasi A Jänne; Tony Mok; Lynette M Sholl; Rebecca S Heist Journal: Lung Cancer Date: 2019-05-11 Impact factor: 5.705
Authors: Alessandro Russo; Ana Rita Lopes; Michael G McCusker; Sandra Gimenez Garrigues; Giuseppina R Ricciardi; Katherine E Arensmeyer; Katherine A Scilla; Ranee Mehra; Christian Rolfo Journal: Curr Oncol Rep Date: 2020-04-16 Impact factor: 5.075
Authors: Ken Suzawa; Michael Offin; Daniel Lu; Christopher Kurzatkowski; Morana Vojnic; Roger S Smith; Joshua K Sabari; Huichun Tai; Marissa Mattar; Inna Khodos; Elisa de Stanchina; Charles M Rudin; Mark G Kris; Maria E Arcila; William W Lockwood; Alexander Drilon; Marc Ladanyi; Romel Somwar Journal: Clin Cancer Res Date: 2018-10-23 Impact factor: 12.531
Authors: Matthew A Smith; Thomas Licata; Aliya Lakhani; Marileila Varella Garcia; Hans-Ulrich Schildhaus; Vincent Vuaroqueaux; Balazs Halmos; Alain C Borczuk; Y Ann Chen; Benjamin C Creelan; Theresa A Boyle; Eric B Haura Journal: Clin Cancer Res Date: 2017-08-29 Impact factor: 12.531